Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)

NCT01591863 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
38
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)